Medpace Holdings Inc
MEDP
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
43.5% upsideUndervalued by 43.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.77 Billion |
|---|---|
| Enterprise Value | $12.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $15.64 |
| Beta | 1.19 |
| Outstanding Shares | 28,445,000 |
Return
| Return on Equity | 76.95% |
|---|---|
| Return on Assets | 21.62% |
| Return on Invested Capital | 72.10% |
Valuation & Multiples
| P/E Ratio | 27.62 |
|---|---|
| PEG | 341.3 |
| Price to Sales | 4.88 |
| Price to Book Ratio | 21.84 |
| Enterprise Value to Revenue | 4.71 |
| Enterprise Value to EBIT | 22.28 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.82 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8568▼ 173.61% |
|---|---|
| Total Calls | 23,804▼ 5.91% |
| Total Puts | 44,200▼ 51.38% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 84.95%▲ 3.13% |
|---|---|
| Total Invested | $11.51B▼ 13.71% |
| Investors Holding | 733▼ 58.00% |
ESG Score
No data
About Medpace Holdings Inc
CEO: August Troendle Relevant Senate Committees
This committee provides crucial analysis and revenue estimates for tax legislation, directly influencing corporate tax structures and capital investment credits, which impact Medpace and its clients' financial planning and investment in R&D.
This powerful committee controls taxation, trade, and Medicare pricing. Tax policy and drug reimbursement rates significantly affect the profitability and R&D investment of Medpace and its pharmaceutical clients.
This committee directly allocates federal spending, including for scientific research (e.g., NIH), which funds the development pipeline for drugs and therapies, directly creating demand for CRO services.
This committee directly regulates the FDA and NIH, which are critical to drug approval processes and funding for biotech R&D, profoundly impacting Medpace's core business.
Members receive classified briefings on global threats, including biological risks, which can directly influence national R&D priorities and funding for biotech, impacting CROs like Medpace.